Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) SEC filings page on Stock Titan provides structured access to the company’s U.S. regulatory disclosures. As a British Columbia–incorporated, globally active pharmaceutical issuer with common shares listed on the New York Stock Exchange and Toronto Stock Exchange, Bausch Health files a variety of documents with the U.S. Securities and Exchange Commission under Commission File Number 001-14956.
Investors can review current reports on Form 8-K that describe material events such as exchange offers for senior secured notes, amendments to credit agreements at Bausch Health and Bausch + Lomb, completion of acquisitions like DURECT Corporation, quarterly financial results, shareholder meeting outcomes and other significant corporate actions. These filings also summarize key terms of new 10.00% Senior Secured Notes due 2032, related indentures and collateral arrangements, including pledges of Bausch + Lomb shares.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically provide more comprehensive detail on Bausch Health’s segments—Salix, International, Solta Medical, Diversified Products and Bausch + Lomb—along with risk factors, management’s discussion and analysis and notes on non-GAAP metrics the company uses, such as organic revenue growth and adjusted EBITDA. Proxy materials and governance-related filings give additional insight into matters like the Amended and Restated Shareholder Rights Plan Agreement and shareholder voting results.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping users understand changes in debt structure, covenant terms, segment performance and strategic transactions without reading every page. Real-time updates from EDGAR, along with visibility into items such as potential insider transaction reports on Form 4, allow users to monitor how Bausch Health reports its financial condition, capital structure decisions and corporate governance developments over time.
Bausch Health Companies Inc. director Amy B. Wechsler received 1,065 restricted share units on 09/30/2025 issued in lieu of cash compensation for board service. Each restricted share unit represents a contingent right to one common share and was reported as having a $0 cash price. After the grant, the reporting person beneficially owned 265,452 common shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Bausch Health Companies Inc. disclosed a contractual mechanism tied to the company’s transaction with DURECT Corporation that grants each share a non-transferable contingent value right (CVR). The CVR represents the holder’s pro rata claim on two milestone payments that together can total up to $350,000,000, after deducting retention bonuses payable to certain DURECT employees if the net sales milestones are met. The filing incorporates a September 11, 2025 joint press release and references a Schedule TO Amendment; contact information for the signatory lists Jean-Jacques Charhon as Executive Vice President and Chief Financial Officer.
Seana Carson, EVP and General Counsel of Bausch Health Companies Inc. (BHC), reported two transactions in a Form 4. On 09/05/2025 the filing shows 51,337 shares were withheld to satisfy tax withholding obligations upon vesting of restricted share units at an indicated price of $7.35, leaving 512,955 shares beneficially owned. On 09/08/2025 the filing shows 13,370 shares sold in the open market pursuant to a Rule 10b5-1 plan at $7.31, reducing beneficial ownership to 499,585 shares.
The Form 4 is signed by an attorney-in-fact on behalf of the reporting person on 09/08/2025. Notes in the filing explicitly state the withholding was for tax obligations on RSU vesting and the sale was executed under a 10b5-1 plan adopted May 7, 2025.
Bausch Health Companies Inc (BHC) filed a Form 144 reporting a proposed sale of 13,370 common shares held at Fidelity Brokerage Services. The filing lists an aggregate market value of $97,734.70 and shows approximately 369,790,319 shares outstanding. The proposed sale is scheduled around 09/08/2025. The shares were acquired on 09/05/2025 through restricted stock vesting and were paid as compensation on the same date. The filer reports no other sales in the past three months and attests to the absence of undisclosed material adverse information.
Bausch Health Companies Inc. (BHC) is soliciting shareholder votes for a Special Meeting to ratify an Amended and Restated Shareholder Rights Plan (the "Rights Agreement"). Shareholders of record as of August 18, 2025 may vote at a virtual Special Meeting scheduled for October 7, 2025. The proxy materials were first mailed on or about August 27, 2025 and are available on the company website and regulatory filers.
The Rights Agreement creates transferable rights attached to each common share that, upon certain triggering events (the "Separation Time" following an "Acquiring Person" obtaining 20% of voting shares or other specified takeover events), become exercisable to purchase common shares at an Exercise Price equal to three times the Market Price (Market Price defined as the 20-day average closing price). The plan contains customary anti-dilution adjustments, a redemption price of $0.00001 per Right, carve-outs for Permitted/Competing Permitted Bids, a requirement to reconfirm the plan every third annual meeting, and other procedural and governance provisions. The filing states 369,800,365 common shares were outstanding as of August 18, 2025 and quorum requires holders of at least 25% of outstanding voting shares.
Lee Frank D., a director of Bausch Health Companies Inc. (BHC), reported the sale of 15,912 common shares in open-market transactions on 08/21/2025 at a weighted average price of $7.66 per share, reducing his beneficial ownership to 73,795 shares. The filing states the shares were sold to provide funds for estimated tax payments arising from a previously vested equity award granted to the issuer's non-employee directors. The reported price range for the multiple transactions was $7.66 to $7.665, and the Form 4 was signed by an attorney-in-fact on 08/22/2025.
Bausch Health Companies Inc (BHC) filed a Form 144 reporting a proposed sale of 15,912 common shares valued at $121,887.71. The shares were acquired on 05/12/2025 through restricted stock vesting as compensation from the issuer. The filer lists an approximate sale date of 08/21/2025 and the broker named is Fidelity Brokerage Services LLC with execution on the NYSE. The filing states there were 369,790,319 shares outstanding at the time and reports no securities sold by the filer in the prior three months. The notice includes the standard insider representation regarding absence of undisclosed material adverse information.
Bausch Health Companies Inc. reported that its Director Appointment and Nomination Agreement with the Icahn Group, originally signed in February 2021, has terminated after the Icahn Group’s net long position in the company’s shares fell below the required threshold in that agreement. A related supplemental letter agreement dated May 20, 2025 also ended. Both terminations were effective August 14, 2025.
In connection with the end of the appointment and nomination agreement, Brett M. Icahn and Steven D. Miller resigned from Bausch Health’s board of directors on August 14, 2025. Mr. Miller also stepped down from the Board’s Audit and Risk Committee. The company states that their resignations did not result from any disagreement with Bausch Health. On August 15, 2025, the company issued a press release describing these matters.
Bausch Health Companies Inc.'s Schedule 13D Amendment No. 7 reports that the group of Icahn-related reporting persons sold substantial holdings and now hold no beneficial interest in the issuer's common stock. On August 14, 2025, Icahn Partners LP sold 20,297,523 shares and Icahn Partners Master Fund LP sold 14,423,595 shares, each at a price of $9.00 per share (including brokerage fees). Following these transactions the reporting persons may be deemed to beneficially own 0 shares and have ceased to be beneficial owners of more than 5% of the class, removing their obligation to report under Rule 13d-1(a).
Paulson & Co. Inc. reports beneficial ownership of 70,755,869 common shares of Bausch Health Companies Inc., representing approximately 19.1% of the outstanding common shares based on 369,790,319 shares disclosed by the issuer. The stake is held through funds advised or managed by Paulson, which retain sole voting and dispositive power over these shares for reporting purposes, while Paulson disclaims direct pecuniary ownership except through those funds. The filing notes recent transactions are listed in an attached exhibit and identifies the issuer's principal executive office in Laval, Quebec. This amendment updates prior Schedule 13D disclosures and clarifies the reporting person’s role as investment manager.